Cargando…
Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
Autores principales: | Chandar, Ashwin, Silk, Ann W, Clark, Joseph I, Daniels, Gregory A, McDermott, David F, Morse, Michael, Wong, Michael KK, Stein, Mark, Mehnert, Janice, Danish, Shabbar, Aung, Sandra, Kaufman, Howard L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645553/ http://dx.doi.org/10.1186/2051-1426-3-S2-P129 |
Ejemplares similares
-
Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015) -
Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014) -
Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
por: Wong, Michael K, et al.
Publicado: (2014) -
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
por: Kaufman, Howard L., et al.
Publicado: (2014) -
High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)